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32Abstract
The use of growth factors for the regeneration of soft and hard tissues has been utilized
extensively in dental medicine over the past decade. Recently our group found that
recombinant human bone morphogenetic protein 9 (rhBMP9) was more osteopromotive than
recombinant human bone morphogenetic protein 2 (rhBMP2) when combined with a
deprotenized bovine bone mineral bone grafting material. The aim of the present in vitro study
was to evaluate the regenerative potential of an absorbable collagen sponge(ACS) specifically
designed for extraction socket healing loaded with rhBMP9 when compared to rhBMP2. The
adsorption and release kinetics of rhBMP2 and rhBMP9 were first investigated by
enzyme‐linked immunosorbent assay quantification. Then, the cellular effects of stromal cell line
(ST2) preosteoblasts were investigated utilizing four groups including rhBMP2 and rhBMP9 at
both low(10 ng/ml) and high(100 ng/ml) concentrations loaded onto ACS. Cellular
attachment(8 hours) and proliferation(1, 3, and 5 days) as well as osteoblast differentiation were
investigated by real‐time polymerase chain reaction (PCR) at 3 and 14 days, alkaline phospha-
tase (ALP) activity at 7 days, and alizarin red staining at 14 days. ACS fully adsorbed both
rhBMP2 and rhBMP9 that were slowly released up to 10 days. Although neither rhBMP2 nor
rhBMP9 had any effects on cell attachment or proliferation, pronounced effects were observed
on osteoblast differentiation. ALP activity was increased seven‐fold with rhBMP2‐high, whereas
a marked 10‐fold and 20‐fold increase was observed with rhBMP9‐low and high loaded to ACS,
respectively. Furthermore, mRNA levels of collagen1, ALP, bone sialoprotein, and osteocalcin
were all significantly higher for rhBMP9 when compared to control or rhBMP2 groups. Alizarin
red staining further confirmed that rhBMP9‐low and high demonstrated marked increases in
mineralization potential when compared to rhBMP2‐high. The results demonstrate the marked
effect of rhBMP9 on osteoblast differentiation when combined with ACS in comparison to
rhBMP2 at doses as much as 10 times lower. Further in vivo studies are necessary to investi-
gate whether the regenerative potential is equally as potent.
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FUJIOKA‐KOBAYASHI ET AL. 33Cicciu, Herford, Cicciu, Tandon, & Maiorana, 2014; Herford, Tandon,
Stevens, Stoffella, & Cicciu, 2013; Ramseier, Rasperini, Batia, &
Giannobile, 2012; Yokota et al., 2014). Examples of these include the
use of platelet‐derived growth factor for periodontal and peri‐implant
defects (Kaigler et al., 2011), enamel matrix derivative for periodontal
intrabony defects (Miron et al., 2016), and fibroblast growth factor
two for periodontal defects (Cochran et al., 2016). One growth factor
that has received widespread use for the regeneration of pure bone
defect is that of bone morphogenetic protein 2 (BMP2) utilized across
many fields of medicine (Carreira et al., 2015; Lin, Lim, Chan,
Giannobile, & Wang, 2015; Schroeder et al., 2016).
In general, BMPs are important pleiotropic proteins playing a piv-
otal role in the commitment and differentiation of osteoprogenitor
cells toward bone forming osteoblasts (Rosen, 2006). Although recom-
binant human (rh)BMP2 is the most widely utilized recombinant BMP
with Food and Drug Administration (FDA)'s approval (Bessa, Casal, &
Reis, 2008a, 2008b; Carreira et al., 2014), many investigators remain
surprised to learn that other BMPs have previously been characterized
as more osteogenic than the currently approved BMP2 or BMP7 (Kang
et al., 2004). In two pioneering study conducted over a decade ago
investigating all 14 BMPs, it was found that BMP6 and BMP9 stimu-
lated the highest alkaline phosphatase (ALP) expression in vitro (Cheng
et al., 2003) and had greater potential for orthotropic ossification
in vivo (Kang et al., 2004). In those studies, the bone‐inducing proper-
ties of all BMPs were reported using adenovirus transfection experi-
ments (gene therapy), an area of research still not approved by the
FDA for clinical use (Balmayor & van Griensven, 2015).
BMP9 (also known as growth differentiation factor 2; GDF2) was
first identified in the developing mouse liver cDNA libraries (Song
et al., 1995) and has since been characterized as the most osteogenetic
BMP showing more bone‐regenerative potential than BMP2, also act-
ing as a major modulator of angiogenesis and chondrogenesis (Blunk
et al., 2003; Lamplot et al., 2013; Leblanc et al., 2011). Although these
previous studies were confirmed only utilizing BMP9‐adenovirus‐
transfected cells not approved by the FDA (Cheng et al., 2003; Kang
et al., 2004; Lamplot et al., 2013; Leblanc et al., 2011), our research
group recently characterized the regenerative potential of rhBMP9 in
comparison to rhBMP2. In two studies, it was found that rhBMP9
demonstrated up to 10 times greater osteogenic differentiation when
compared to rhBMP2 (Fujioka‐Kobayashi et al., 2016a, 2016b). These
prominent findings bring intriguing new possibilities for future clinical
application for the treatment of large bone defects in either medicine
or dentistry.
Dimensional change of alveolar bone following tooth loss has been
one of the most highly conveyed clinical challenge documented in den-
tistry for over 50 years (Araújo & Lindhe, 2005; Chappuis et al., 2013;
Johnson, 1963). Many reports over the past decade have attempted
to minimize these effects via a variety of procedures including collagen
barrier membranes, bone grafting materials and growth factors (Bayat,
Momen Heravi, Mahmoudi, & Bahrami, 2015; Brkovic et al., 2008;
Brkovic et al., 2012; Coomes et al., 2014; Fiorellini et al., 2005; Mardas,
Chadha, & Donos, 2010; Mardas, D'Aiuto, Mezzomo, Arzoumanidi, &
Donos, 2011; Misch, 2010; Wallace, 2015; Wallace, Pikos, & Prasad,
2014). Despite this, tooth loss remains a prominent challenge, and no
single therapy has been shown capable of predictably preventingdimensional bone‐changes following extraction (De Risi, Clementini,
Vittorini, Mannocci, & De Sanctis, 2015; Jambhekar, Kernen, & Bidra,
2015; Moraschini & Barboza, 2016; Morjaria, Wilson, & Palmer, 2014;
Spagnoli & Choi, 2013; Tan, Wong, Wong, & Lang, 2012).
One low‐cost method utilized for the healing of extraction sockets
by creating homeostasis is by placing an absorbable collagen sponge
(ACS) into fresh sockets (Coomes et al., 2014). Advantages of ACS
apart from their low‐cost include their stable and moldable cone‐
shaped sizes, their natural collagen scaffolds, their ability to facilitate
blood clot formation through hemostatic wound coverage, and their
ability to remain rapidly and fully resorbable over time (Coomes
et al., 2014). Although these properties are all contributing factors to
extraction socket preservation and healing, one of their other advan-
tages includes their ability to serve as a carrier system for growth fac-
tors due to their natural collagen structure (Coomes et al., 2014; De
Sarkar et al., 2015; Spagnoli & Choi, 2013; Zhang et al., 2015).
In light of these advantages and due to the reported clinical chal-
lenges faced in daily clinical practice, the aim of the present study was
to assess the regenerative potential of ACS loaded with rhBMP9. In a
first step study, the regenerative potential of rhBMP9was directly com-
pared to rhBMP2 and investigated on in vitro adsorption and release of
BMP9 from ACS. Thereafter, preosteoblasts were investigated for their
ability to attach, proliferate, and differentiate onto ACS loaded with
either rhBMP9 or rhBMP2 in two different concentrations each.2 | MATERIAL AND METHODS
2.1 | Absorbable collagen sponges and rhBMP2 and
rhBMP9
Recombinant human BMP2 and rhBMP9 were purchased from R&D
systems Inc (Minneapolis, MM, USA). ACS, porcine‐origin native types
I and III porcine collagen sponge, were kindly provided by Botiss AG,
Germany (collacone®). Figure S1 demonstrates a scanning electron
microscopy (SEM) image used to characterize surface shape and topog-
raphy as previously described (Miron et al., 2011). For all in vitro exper-
iments, the following six groups were used: (a) control standard tissue
culture plastic (TCP), (b) control ACS alone, (c) ACS loadedwith low con-
centration (10 ng/ml) of rhBMP2, (d)ACS loaded with high concentra-
tion (100 ng/ml) of rhBMP2, (e) ACS loaded with low concentration
(10 ng/ml) of rhBMP9, and (f) ACS loaded with high concentration
(100 ng/ml) of rhBMP9. Undifferentiated mouse cell‐line ST2 was
obtained from RIKEN Cell Bank (Tsukuba, Japan) and therefore no eth-
ical approval was necessary for the present study. Cells were cultured in
a humidified atmosphere at 37 °C in growth medium consisting of
Dulbecco's modified eagle's medium (DMEM; Invitrogen Corporation,
Carlsbad, CA), 10% fetal Bovine serum (FBS; Invitrogen), and antibiotics
(Invitrogen). For in vitro experiments, ACSs were cut in 1 mm thick cyl-
inders to fit into the bottom of 24 well dishes and coated with rhBMP2
or rhBMP9 for 5 min prior to cell seeding. Thereafter, cells were seeded
onto the various treatment modalities at a density of 10,000 cells in 24
well culture plates for cell adhesion and proliferation experiments and
50,000 cells per well in 24 well dishes for real‐time PCR, ALP assay,
and alizarin red experiments. For experiments lasting longer than
5 days, medium was replaced twice weekly.
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rhBMP9 adsorption to absorbable collagen sponges
To determine the quantity of rhBMP2 and rhBMP9 adsorption to the
surface of ACS, enzyme‐linked immunosorbent assay (ELISA) quantifi-
cation assay was utilized. Briefly, the coating period incubation of both
100 ng/mL of rhBMP2 and rhBMP9 onto ACS at 37 °C in a shaking incu-
bator. The remaining Phosphate Buffered Solution (PBS), containing
unattached protein, was collected and quantified by a sandwich ELISA,
BMP2 (DY355, range = 46.90–3,000 pg/ml, R&D Systems, Minneapolis,
MN, USA), and BMP9 (DY3209, range = 15.60–1,000 pg/ml, R&D Sys-
tems) for the amount of rhBMP2/rhBMP9 protein unadsorbed to ACS
according to manufacturer's protocol. The 100 ng/ml of rhBMP2 and
rhBMP9 in PBSwas quantified by ELISA, and the amount of each protein
was considered as positive control (total coated protein). Subtraction of
total coated protein from the amount of unadsorbed protein was used
to determine the amount of adsorbed material to the surface of ACS as
previously described (Miron et al., 2015). Furthermore, in order to deter-
mine the quantity of rhBMP2 and rhBMP9 protein being released from
ACS over time, coated ACS were soaked in 1 ml of PBS, and samples
were collected at various time points including 15 min, 1 hr, 8 hrs, 1, 3,
and 10 days. All samples were quantified in duplicate, and three indepen-
dent experiments were performed.TABLE 1 Polymerase chain reaction primers for genes encoding runt‐
related transcription factor, collagen 1 alpha 2, alkaline phosphatase,




mRUNX2 R Ggctcacgtcgctcatctt2.3 | Adhesion and proliferation assay
ST2 cells were seeded in 24 well plates at a density of 10,000 cells per
well in either (a) control standard TCP, (b) control ACS alone, (c) have
ACS loaded with low concentration (10 ng/ml) of rhBMP2, (d) have
ACS loaded with high concentration (100 ng/ml) of rhBMP2, (e)
have ACS loaded with low concentration (10 ng/ml) of rhBMP9, or (f)
high concentration (100 ng/ml) of rhBMP9. Cells were quantified using
MTS assay (3‐(4,5‐dimethylthiazol‐2‐yl)‐5‐(3‐carboxymethoxyphenyl)‐
2‐(4‐sulfophenyl)‐2H‐tetrazolium) (Promega, Madison, WI) at 8 hrs for
cell adhesion and at 1, 3, and 5 days for cell proliferation as previously
described (Miron, Saulacic, Buser, Iizuka, & Sculean, 2013). At desired
time points, cells were washed with PBS and quantified using an
ELx808 Absorbance Reader (BIO‐TEK, Winooski, VT). Experiments
were performed in triplicate with three independent experiments for
each condition. Data were analyzed for statistical significance using
one‐way analysis of variance for adhesion assay and two‐way analysis
of variance with Turkey test for proliferation assay (*, p values <.05










Note. Runx2 = encoding runt‐related transcription factor; COL1a2 = colla-
gen 1 alpha 2; ALP = alkaline phosphatase; BSP = bone sialoprotein;
OCN = osteocalcin; GAPDH = glyceraldehyde 3‐phosphate dehydrogenase2.4 | ALP activity assay
ST2 cells were stimulated on ACS with/without rhBMP in growth
media. At 7 days, cells were quantified for ALP expression as deter-
mined cell imaging. ALP activity was monitored using leukocyte alka-
line phosphatase kit (procedure No. 86, Sigma). ST2 cells were fixed
by immersing in a citrate‐acetone‐formaldehyde fixative solution for
5 min and rinsed in deionized water for 1 min. Alkaline dye mixture
are prepared by 1 ml Sodium Nitrite Solution and 1 ml fast red violet
alkaline solution dissolved in 45 ml of distilled water and 1 ml of
Naphtol AS‐Bl alkaline solution. Surfaces were then placed in alkaline
dye mixture solution for 15 min protected from light. Following2 min of rinsing in deionized water. All images were captured on aWild
Heerbrugg M400 ZOOM Makroskop (WILD HEERBRUGG, Switzer-
land) at the same magnification at the same light intensity and
imported onto Image J software (NIH, Bethesda, MD). Thresholding
was used to generate percent‐stained values for each field of view.2.5 | Real‐time PCR for osteoblast differentiation
markers
Real‐time RT‐PCR was used to investigate the expression of genes
encoding osteoblast differentiation markers. Total RNA was isolated
using High Pure RNA Isolation Kit (Roche, Basel, Switzerland) at 3
and 14 days. Primer and probe sequences for genes encoding runt‐
related transcription factor 2, collagen1α2 (COL1a2), ALP, bone
sialoprotein (BSP), osteocalcin (OCN) and glyceraldehyde 3‐phosphate
dehydrogenase were fabricated with Primer sequences according to
Table 1. Reverse transcription was performed with Transcriptor First
Strand cDNA Synthesis Kit (Roche). Real‐time RT‐PCR was performed
using Roche FastStart Universal SYBR Green Master and quantified on
an Applied Biosystems 7500 Real‐Time PCRMachine (Biosystems, Life
Technologies Corporation, Carlsbad, CA). A Nanodrop 2000c (Thermo,
Wilmington, DE) was used to quantify total RNA levels. All samples
were assayed in duplicate with three independent experiments were
performed. The ΔΔCt method was used to calculate gene expression
levels normalized to mRNA level of glyceraldehyde 3‐phosphate dehy-
drogenase and calibrated to control samples. Data were analyzed for
statistical significance using two‐way analysis of variance with Tukey
test (*, p values <.05 was considered significant).2.6 | Alizarin red staining
ST2 cells were stimulated on ACS for 14 days with/without rhBMP in
osteogenic differentiation medium, which consisted of DMEM supple-
mented with 10% FBS, 1% antibiotics, 50 μg/ml ascorbic acid (Sigma)
and 10 mM β‐glycerophosphate (Sigma) to promote osteoblast
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presence of extracellular matrix mineralization. After 14 days, cells
were fixed in 96% ethanol for 15 min and stained with 0.2% alizarin
red (Alizarin red S; Sigma) solution in water (pH 6.4) at room tempera-
ture for 1 hr as previously described (Fujioka‐Kobayashi et al., 2016a).
Alizarin red quantification was performed using images captured on a
Nikon D610 camera with a Heerbrugg M400 ZOOMmicroscope (Wild
Heerbrugg, Switzerland). The same threshold values were used for all
analyzed. Means and standard errors were calculated, and the statisti-
cal significance of differences was examined by one‐way analysis with
Tukey test between both groups (*, p values <.05 was considered
significant).3 | RESULTS
3.1 | Surface characteristics of absorbable collagen
sponges and ability to adsorb and release rhBMP2 and
rhBMP9 over time
First, the surface morphology and characteristics of ACS were investi-
gated via low and high magnification SEM (Figure S1). It was found at
low magnification that the three‐dimensional surface architecture of
ACS resembled a “honeycomb”‐shaped morphology fabricated from
collagen fibrils (Figure S1). The high‐resolution SEM images further
demonstrated the numerous collagen fibers found on the surface of
ACS scaffolds (Figure S1). Thereafter, the adsorption and release kinet-
ics of both rhBMP2 and rhBMP9 were investigated at various time
points ranging from zero to 10 days (Figure 1). ACSs were able to
adsorb nearly 90% of total protein content of rhBMP2 and rhBMP9.
Over time, ACS displayed a feature of slowly dissolving and releasing
rhBMP2 or rhBMP9 over a 10‐day (Figure 1). No differences in growth
factor adsorption could be observed between rhBMP2 and rhBMP9
(Figure 1). At the end of the experiment (10 days), approximately
20% of the initial growth factor concentration remained present within
the collagen scaffolds demonstrating a slow and consistent release of
either rhBMP2 or rhBMP9 over time (Figure 1).FIGURE 1 Growth factor adsorption of recombinant human bone
morphogenetic protein 2 and recombinant human bone
morphogenetic protein 9to absorbable collagen sponges at 0 min,
15 min, 60 min, 8 hrs, 24 hrs, 3 days, and 10 days as quantified by
enzyme‐linked immunosorbent assay. absorbable collagen sponges
were able to efficiently adsorb recombinant bone morphogenetic
protein 2 and bone morphogenetic protein 9 and have comparable
release kinetics over time3.2 | Effect of absorbable collagen sponges on ST2
cell adhesion and proliferation when combined with
rhBMP2 or rhBMP9
Thereafter, ST2 preosteoblasts were seeded directly onto ACS and
investigated for cell adhesion at 8 hrs (Figure 2a) and cell proliferation
at 1, 3 and 5 days postseeding (Figure 2b). It was first found that cells
attached efficiently to ACS in a near 100% value when compared to
standard TCP (Figure 2a). No differences could be observed between
control TCP, control ACS as well as any of the groups containing
rhBMP2 or rhBMP9 (Figure 2a). Furthermore, the effects of rhBMP2
and rhBMP9 had no influence on the proliferation of preosteoblasts
at either 1, 3, or 5 days postseeding (Figure 2b).3.3 | Effect of absorbable collagen sponges on ST2
cell differentiation when combined with rhBMP2 or
rhBMP9
The effects of rhBMP2 and rhBMP9 were investigated on ST2 cell
differentiation to osteoblasts (Figure 3–5). It was observed that ACS
coated with either rhBMP2 high or rhBMP9 (low or high) demon-
strated significantly higher ALP staining when compared to control
TCP, control ACS, and ACS coated with rhBMP2 low at a concentra-
tion of 10 ng/ml. The ACS loaded with rhBMP2 high (100 ng/ml)FIGURE 2 (a) Attachment (8 hrs) and (b) proliferation (1, 3, and 5 days)
assays of ST2 cells seeded on control tissue culture plastic, control
absorbable collagen sponges (ACS), ACS loaded with bone
morphogenetic protein 2 low (10 ng/ml), ACS loaded with
bone morphogenetic protein 2 high (100 ng/ml), ACS loaded with bone
morphogenetic protein 9 low (10 ng/ml), and ACS loaded with bone
morphogenetic protein 9 high (100 ng/ml). No significant
difference was observed between six groups at all time points
FIGURE 3 (a) Alkaline phosphatase staining
of absorbable collagen sponges (ACS) at
7 days of ST2 cells seeded on control tissue
culture plastic, control ACS, ACS loaded with
BMP2 low (10 ng/ml), ACS loaded with BMP2
high (100 ng/ml), ACS loaded with BMP9 low
(10 ng/ml), and ACS loaded with BMP9 high
(100 ng/ml). (b) bone morphogenetic protein 9
low and high significantly increased alkaline
phosphatase staining when compared to
control and bone morphogenetic protein
2samples (* denotes significant difference,
p < .05; ** denotes significantly higher than all
other treatment modalities, p < .05)
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pared to controls (Figure 3). Interestingly, rhBMP9 low demonstrated
a 1.5‐fold increase when compared to rhBMP2 high (representing a
one‐fold lower concentration of rhBMP9 low (10 ng/ml) when com-
pared to rhBMP2 high (100 ng/ml)). ACS loaded with rhBMP9 high
(100 ng/ml) demonstrated significantly higher ALP staining when
compared to all other groups representing up to a 20‐fold significant
increase when compared to control samples and a 2.5 fold significant
increase when compared to rhBMP2 at the same concentration
(100 ng/ml; Figure 3).
Thereafter, real‐time PCR was utilized to investigate osteoblast
differentiation markers at 3 and 14 days post seeding (Figure 4). While
runt‐related transcription factor 2 demonstrated no differences
between all groups at either time point (Figure 4a), COL1a2 demon-
strated significantly higher levels of rhBMP9 high when compared to
control ACS at 3 days (Figure 4b). The mRNA levels of ALP further
demonstrated significantly higher values for rhBMP9 low, rhBMP9
high and rhBMP2 high when compared to control TCP, control ACS
alone, and ACS loaded with rhBMP2 low (Figure 4c). No differences
could be observed between any groups by 14 days (Figure 4c). Late
osteoblast differentiation markers including BSP and OCN both dem-
onstrated significantly higher levels in the rhBMP9 high group at
14 days postseeding (Figure 4d,e).
In a final experiment, alizarin red staining was utilized to investi-
gate the mineralization potential of each group over a 14 day period
(Figure 5). It was observed that the groups preloaded with rhBMP9
performed significantly better than rhBMP2 and control groups
(Figure 5). rhBMP9 low (10 ng/ml) demonstrated over a two‐fold
increase in alizarin red staining when compared to rhBMP2 high
(100 ng/ml) (Figure 5). Furthermore, rhBMP9 high demonstrated up
to a four‐fold increase when compared to rhBMP2 high (Figure 5).4 | DISCUSSION
The aim of the present study was to investigate the biocompatibility of
ACS and their ability to promote osteoblast differentiation when com-
bined with rhBMP2 and rhBMP9. The use of ACS shaped in cylindrical
format has been utilized in modern dentistry to facilitate wound healing
in extraction sockets. Although numerous scientific reports have now
documented the effects of tooth loss on dimensional changes of alveo-
lar bone (Araújo & Lindhe, 2005; Chappuis et al., 2013; De Risi et al.,
2015; Jambhekar et al., 2015; Moraschini & Barboza, 2016; Morjaria
et al., 2014; Spagnoli & Choi, 2013; Tan et al., 2012), there remains a
lack of options to predictably regenerate lost bone following tooth loss.
For these reasons, a variety of treatment options and various biomate-
rials have been investigated to minimize bone loss following tooth
extraction (Bayat et al., 2015; Brkovic et al., 2008; Brkovic et al.,
2012; Coomes et al., 2014; Fiorellini et al., 2005; Mardas et al., 2010;
Mardas et al., 2011; Misch, 2010; Wallace, 2015; Wallace et al., 2014).
One available option for regenerating missing bone is the use of
BMPs which has been exploited as a recombinant growth factor source
for a variety of bone augmentation procedures including guided bone
regeneration, sinus augmentation, and vertical and horizontal augmen-
tation procedures (Draenert, Nonnenmacher, Kammerer, Goldschmitt,
& Wagner, 2013; Fiorellini et al., 2005; Leknes et al., 2008; Schwarz
et al., 2008). Numerous previous research have further demonstrated
that the optimal loading carrier system for recombinant growth factors
continues to be the use of scaffolds containing collagen matrix such as
ACS (Coomes et al., 2014; De Sarkar et al., 2015; Spagnoli & Choi,
2013; Zhang et al., 2015).
In the present study, it was found via SEM that these ACS had a
very porous surface structure demonstrating a honeycomb‐shaped
surface morphology at low magnificent; important features for growth
FIGURE 4 Real‐time PCR of ST2 cells seeded on control tissue culture plastic, control absorbable collagen sponges (ACS), ACS loaded with BMP2
low (10 ng/ml), ACS loaded with BMP2 high (100 ng/ml), ACS loaded with BMP9 low (10 ng/ml), and ACS loaded with BMP9 high (100 ng/ml) for
genes encoding (a) runt‐related transcription factor 2, (b) collagen 1 alpha 2 (COL1a2), (c) alkaline phosphatase (ALP), (d) bone sialoprotein (BSP),
and (e) osteocalcin (OCN) at 3 and 14 days postseeding (* denotes significant difference, p < .05; ** denotes significantly higher than all other
treatment modalities, p < .05)
FUJIOKA‐KOBAYASHI ET AL. 37factor adsorption as well as penetration of progenitor cells into the
material surface (Figure S1). Furthermore, the growth factor adsorp-
tion properties and release kinetics further demonstrated the favorable
loading of either rhBMP2 or rhBMP9 and the ability for the biomaterial
to hold and release the growth factor over a 10 day period (Figure 1).
The ability for growth factors to adsorb better to ACS when compared
to mineralized bone grafting particles has previously been investigated
by our group (Miron et al., 2015). Along with unpublished data from
our laboratory, it was also found that rhBMP9 adsorbed more effi-
ciently to ACS when compared to a variety of other bone grafting par-
ticles including demineralized freeze dried bone allograft, a natural
bone mineral of bovine origin and calcium phosphate biomaterials.
One of the major challenges faced to date with the use of recom-
binant BMP2 is the number of reported secondary side effects includ-
ing less than optimal bone volume and density, edema, and
inflammation have been associated with their high dosage (Tannoury
& An, 2014). For these reasons, more efficient growth factors that
may be utilized in lower doses would present a major breakthrough
in regenerative medicine in the bone biology fields.Recently, our group found that rhBMP9 induced significantly
higher osteoblast differentiation potential when compared to rhBMP2.
In the present investigation, we utilized these preliminary findings and
attempt to optimize the results by combining rhBMP9 with ACS scaf-
folds. In the present study, we found that rhBMP9 even at low concen-
trations of 10 ng/ml was able to significantly induce over a two‐fold
increase in osteoblast differentiation when compared to rhBMP2 at a
high concentration of 100 ng/ml. Furthermore, positive results were
also observed for experiments investigating mRNA levels of osteoblast
differentiation markers as well as mineralization potential investigated
via alizarin red staining. Therefore, it may be hypothesized that based
on these positive results, lower concentrations of rhBMP9 could
potentially be utilized to induce new bone formation when compared
to rhBMP2. The difference in osteogenic behavior between BMP2
and BMP9 was addressed previously by several pathway variances
according to adenovirus experiments. BMP antagonist, noggin
inhibited BMP2 osteogenesis, however SMAD phosphorylation by
BMP9 was not inhibited by exogenous noggin (Bergeron et al., 2009;
Nakamura, Shinohara, Momozaki, Yoshimoto, & Noguchi, 2013; Wang
FIGURE 5 (a) Visual representation of alizarin
red‐stained of negative control absorbable
collagen sponges (ACS) without cells, control
tissue culture plastic, control ACS, ACS loaded
with BMP2 low (10 ng/ml), ACS loaded with
BMP2 high (100 ng/ml), ACS loaded with
BMP9 low (10 ng/ml), and ACS loaded with
BMP9 high (100 ng/ml) at 14 days
postseeding. Note the intensity of red staining
of ACS coated with BMP9 in comparison to
control and BMP2 samples. (b) Quantified data
of alizarin red staining from colour
thresholding software (* denotes significant
difference, p < .05; ** denotes significantly
higher than all other treatment modalities,
p < .05)
38 FUJIOKA‐KOBAYASHI ET AL.et al., 2013). BMP3, a known BMP2 inhibitor, did not inhibit BMP9‐
mediated bone formation (Kang et al., 2004). Further research utilizing
rhBMP9 would benefit our understanding on the differential mecha-
nisms that regulate osteogenesis in both BMP2 versus BMP9. One
group currently reported that rhBMP9 loaded on atelocollagen and
chitosan sponges promoted new bone formation in rat critical‐sized
bone defect (Toshiaki Nakamura et al., 2016; Shinohara, Nakamura,
Shirakata, & Noguchi, 2016). The further animal studies in comparison
with rhBMP2 are now necessary to further verify bone regenerative
potential of rhBMP9.
The findings from the present study demonstrate that ACS
loaded with either rhBMP2 or rhBMP9 were able to efficiently
adsorb both growth factors onto ACS over a 10‐day period and
induce osteoblast differentiation. Noteworthy, rhBMP9 was able to
stimulate over a two‐fold increase in osteoblast differentiation at
low doses (10 ng/ml) when compared to rhBMP2 at high doses
(100 ng/ml). Future animal studies are now needed to investigate
the regenerative potential of rhBMP9 in combination with ACS to min-
imize dimensional changes in extraction sockets following tooth loss.
CONFLICT OF INTEREST
All authors affirm that they have no conflict of interest.
REFERENCE
Alonso, N., Tanikawa, D. Y., Freitas Rda, S., Canan, L. Jr., Ozawa, T. O., &
Rocha, D. L. (2010). Evaluation of maxillary alveolar reconstruction
using a resorbable collagen sponge with recombinant human bone mor-
phogenetic protein‐2 in cleft lip and palate patients. Tissue Engineering.
Part C, Methods, 16(5), 1183–1189. doi:10.1089/ten.TEC.2009.0824
Araújo, M. G., & Lindhe, J. (2005). Dimensional ridge alterations following
tooth extraction. An experimental study in the dog. Journal of Clinical
Periodontology, 32(2), 212–218.
Balmayor, E. R., & van Griensven, M. (2015). Gene therapy for bone engi-
neering. Frontiers in Bioengineering and Biotechnology, 3, 9.
doi:10.3389/fbioe.2015.00009Bayat, M., Momen Heravi, F., Mahmoudi, M., & Bahrami, N. (2015). Bone
reconstruction following application of bone matrix gelatin to alveolar
defects: A randomized clinical trial. International Journal of Organ Trans-
plantation Medicine, 6(4), 176–181.
Behnia, H., Khojasteh, A., Soleimani, M., Tehranchi, A., & Atashi, A. (2012).
Repair of alveolar cleft defect with mesenchymal stem cells and platelet
derived growth factors: A preliminary report. Journal of Cranio‐Maxillo‐
Facial Surgery, 40(1), 2–7. doi:10.1016/j.jcms.2011.02.003
Bergeron, E., Senta, H., Mailloux, A., Park, H., Lord, E., & Faucheux, N.
(2009). Murine preosteoblast differentiation induced by a peptide
derived from bone morphogenetic proteins‐9. Tissue Engineering. Part
A, 15(11), 3341–3349. doi:10.1089/ten.TEA.2009.0189
Bessa, P. C., Casal, M., & Reis, R. L. (2008a). Bone morphogenetic proteins
in tissue engineering: The road from the laboratory to the clinic, part I
(basic concepts). Journal of Tissue Engineering and Regenerative Medicine,
2(1), 1–13. doi:10.1002/term.63
Bessa, P. C., Casal, M., & Reis, R. L. (2008b). Bone morphogenetic proteins
in tissue engineering: The road from laboratory to clinic, part II (BMP
delivery). Journal of Tissue Engineering and Regenerative Medicine,
2(2–3), 81–96. doi:10.1002/term.74
Blunk, T., Sieminski, A. L., Appel, B., Croft, C., Courter, D. L., Chieh, J. J., …
Gooch, K. J. (2003). Bone morphogenetic protein 9: A potent modulator
of cartilage development in vitro. Growth Factors, 21(2), 71–77.
Brkovic, B. M., Prasad, H. S., Konandreas, G., Milan, R., Antunovic, D.,
Sandor, G. K., & Rohrer, M. D. (2008). Simple preservation of a maxillary
extraction socket using beta‐tricalcium phosphate with type I collagen:
Preliminary clinical and histomorphometric observations. Journal of the
Canadian Dental Association, 74(6), 523–528.
Brkovic, B. M., Prasad, H. S., Rohrer, M. D., Konandreas, G., Agrogiannis, G.,
Antunovic, D., & Sandor, G. K. (2012). Beta‐tricalcium phosphate/type I
collagen cones with or without a barrier membrane in human extraction
socket healing: Clinical, histologic, histomorphometric, and immunohis-
tochemical evaluation. Clinical Oral Investigations, 16(2), 581–590.
doi:10.1007/s00784-011-0531-1
Carreira, A. C., Lojudice, F. H., Halcsik, E., Navarro, R. D., Sogayar, M. C., &
Granjeiro, J. M. (2014). Bone morphogenetic proteins: Facts, challenges,
and future perspectives. Journal of Dental Research, 93(4), 335–345.
doi:10.1177/0022034513518561
Carreira, A. C., Zambuzzi, W. F., Rossi, M. C., Astorino Filho, R., Sogayar, M.
C., & Granjeiro, J. M. (2015). Bone morphogenetic proteins: Promising
FUJIOKA‐KOBAYASHI ET AL. 39molecules for bone healing, bioengineering, and regenerative medicine.
Vitamins and Hormones, 99, 293–322. doi:10.1016/bs.vh.2015.06.002
Chappuis, V., Engel, O., Reyes, M., Shahim, K., Nolte, L. P., & Buser, D.
(2013). Ridge alterations post‐extraction in the esthetic zone: A 3D
analysis with CBCT. Journal of Dental Research, 92(12 Suppl), 195s–
201s. doi:10.1177/0022034513506713
Cheng, H., Jiang, W., Phillips, F. M., Haydon, R. C., Peng, Y., Zhou, L., … He,
T. C. (2003). Osteogenic activity of the fourteen types of human bone
morphogenetic proteins (BMPs). The Journal of Bone and Joint Surgery.
American Volume, 85‐a(8), 1544–1552.
Cicciu, M., Herford, A. S., Cicciu, D., Tandon, R., & Maiorana, C. (2014).
Recombinant human bone morphogenetic protein‐2 promote and
stabilize hard and soft tissue healing for large mandibular new bone
reconstruction defects. The Journal of Craniofacial Surgery, 25(3),
860–862. doi:10.1097/scs.0000000000000830
Cochran, D. L., Oh, T. J., Mills, M. P., Clem, D. S., McClain, P. K., Schallhorn,
R. A., … Takemura, A. (2016). A randomized clinical trial evaluating rh‐
FGF‐2/beta‐TCP in periodontal defects. Journal of Dental Research,
95(5), 523–530. doi:10.1177/0022034516632497
Coomes, A. M., Mealey, B. L., Huynh‐Ba, G., Barboza‐Arguello, C., Moore,
W. S., & Cochran, D. L. (2014). Buccal bone formation after flapless
extraction: a randomized, controlled clinical trial comparing recombi-
nant human bone morphogenetic protein 2/absorbable collagen
carrier and collagen sponge alone. Journal of Periodontology, 85(4),
525–535. doi:10.1902/jop.2013.130207
De Risi, V., Clementini, M., Vittorini, G., Mannocci, A., & De Sanctis, M.
(2015). Alveolar ridge preservation techniques: A systematic review
and meta‐analysis of histological and histomorphometrical data. Clinical
Oral Implants Research, 26(1), 50–68. doi:10.1111/clr.12288
De Sarkar, A., Singhvi, N., Shetty, J. N., Ramakrishna, T., Shetye, O., Islam,
M., & Keerthy, H. (2015). The local effect of Alendronate with intra‐
alveolar collagen sponges on post extraction alveolar ridge Resorption:
A clinical trial. Journal of Maxillofac Oral Surgery, 14(2), 344–356.
doi:10.1007/s12663-014-0633-9
Draenert, F. G., Nonnenmacher, A. L., Kammerer, P. W., Goldschmitt, J., &
Wagner, W. (2013). BMP‐2 and bFGF release and in vitro effect on
human osteoblasts after adsorption to bone grafts and biomaterials.
Clinical Oral Implants Research, 24(7), 750–757. doi:10.1111/j.1600-
0501.2012.02481.x
Fiorellini, J. P., Howell, T. H., Cochran, D., Malmquist, J., Lilly, L. C., Spagnoli,
D., … Nevins, M. (2005). Randomized study evaluating recombinant
human bone morphogenetic protein‐2 for extraction socket augmenta-
tion. Journal of Periodontology, 76(4), 605–613. doi:10.1902/
jop.2005.76.4.605
Fujioka‐Kobayashi, M., Sawada, K., Kobayashi, E., Schaller, B., Zhang, Y., &
Miron, R. J. (2016a). Osteogenic potential of rhBMP9 combined with
a bovine‐derived natural bone mineral scaffold compared to rhBMP2.
Clinical Oral Implants Research. doi:10.1111/clr.12804
Fujioka‐Kobayashi, M., Sawada, K., Kobayashi, E., Schaller, B., Zhang, Y., &
Miron, R. J. (2016b). Recombinant human bone morphogenetic protein
9 (rhBMP9) induced osteoblastic behaviour on a collagen membrane
compared with rhBMP2. Journal of Periodontology, 1–14. doi:10.1902/
jop.2016.150561
Herford, A. S., Tandon, R., Stevens, T. W., Stoffella, E., & Cicciu, M. (2013).
Immediate distraction osteogenesis: the sandwich technique in combi-
nation with rhBMP‐2 for anterior maxillary and mandibular defects.
The Journal of Craniofacial Surgery, 24(4), 1383–1387. doi:10.1097/
SCS.0b013e318292c2ce
Jambhekar, S., Kernen, F., & Bidra, A. S. (2015). Clinical and histologic out-
comes of socket grafting after flapless tooth extraction: A systematic
review of randomized controlled clinical trials. The Journal of Prosthetic
Dentistry, 113(5), 371–382. doi:10.1016/j.prosdent.2014.12.009
Johnson, K. (1963). A study of the dimensional changes occurring in the
maxilla after tooth extraction.—part I. Normal healing. Australian Dental
Journal, 8(5), 428–433.Kaigler, D., Avila, G., Wisner‐Lynch, L., Nevins, M. L., Nevins, M., Rasperini,
G., … Giannobile, W. V. (2011). Platelet‐derived growth factor applica-
tions in periodontal and peri‐implant bone regeneration. Expert
Opinion on Biological Therapy, 11(3), 375–385. doi:10.1517/
14712598.2011.554814
Kang, Q., Sun, M. H., Cheng, H., Peng, Y., Montag, A. G., Deyrup, A. T., …
He, T. C. (2004). Characterization of the distinct orthotopic bone‐
forming activity of 14 BMPs using recombinant adenovirus‐mediated
gene delivery. Gene Therapy, 11(17), 1312–1320. doi:10.1038/sj.
gt.3302298
Lamplot, J. D., Qin, J., Nan, G., Wang, J., Liu, X., Yin, L., … He, T. C. (2013).
BMP9 signaling in stem cell differentiation and osteogenesis. American
Journal of Stem Cells, 2(1), 1–21.
Leblanc, E., Trensz, F., Haroun, S., Drouin, G., Bergeron, E., Penton, C. M., …
Grenier, G. (2011). BMP‐9‐induced muscle heterotopic ossification
requires changes to the skeletal muscle microenvironment. Journal of
Bone and Mineral Research, 26(6), 1166–1177. doi:10.1002/jbmr.311
Leknes, K. N., Yang, J., Qahash, M., Polimeni, G., Susin, C., & Wikesjo, U. M.
(2008). Alveolar ridge augmentation using implants coated with recom-
binant human bone morphogenetic protein‐2: Radiographic
observations. Clinical Oral Implants Research, 19(10), 1027–1033.
doi:10.1111/j.1600-0501.2008.01567.x
Lin, G. H., Lim, G., Chan, H. L., Giannobile, W. V., & Wang, H. L. (2015).
Recombinant human bone morphogenetic protein 2 outcomes for max-
illary sinus floor augmentation: A systematic review and meta‐analysis.
Clinical Oral Implants Research. doi:10.1111/clr.12737
Mardas, N., Chadha, V., & Donos, N. (2010). Alveolar ridge preservation
with guided bone regeneration and a synthetic bone substitute or a
bovine‐derived xenograft: A randomized, controlled clinical trial. Clinical
Oral Implants Research, 21(7), 688–698. doi:10.1111/j.1600-
0501.2010.01918.x
Mardas, N., D'Aiuto, F., Mezzomo, L., Arzoumanidi, M., & Donos, N. (2011).
Radiographic alveolar bone changes following ridge preservation with
two different biomaterials. Clinical Oral Implants Research, 22(4), 416–
423. doi:10.1111/j.1600-0501.2010.02154.x
Miron, R. J., Hedbom, E., Saulacic, N., Zhang, Y., Sculean, A., Bosshardt, D. D.,
& Buser, D. (2011). Osteogenic potential of autogenous bone grafts
harvested with four different surgical techniques. Journal of Dental
Research, 90(12), 1428–1433. doi:10.1177/0022034511422718
Miron, R. J., Saulacic, N., Buser, D., Iizuka, T., & Sculean, A. (2013). Osteo-
blast proliferation and differentiation on a barrier membrane in
combination with BMP2 and TGFbeta1. Clinical Oral Investigations,
17(3), 981–988. doi:10.1007/s00784-012-0764-7
Miron, R. J., Bosshardt, D. D., Buser, D., Zhang, Y., Tugulu, S., Gemperli, A.,
… Sculean, A. (2015). Comparison of the capacity of enamel matrix
derivative gel and enamel matrix derivative in liquid formulation to
adsorb to bone grafting materials. Journal of Periodontology, 86(4),
578–587. doi:10.1902/jop.2015.140538
Miron, R. J., Sculean, A., Cochran, D. L., Froum, S., Zucchelli, G., Nemcovsky,
C., … Bosshardt, D. D. (2016). 20 years of enamel matrix derivative: The
past, the present and the future. Journal of Clinical Periodontology.
doi:10.1111/jcpe.12546
Misch, C. M. (2010). The use of recombinant human bone morphogenetic
protein‐2 for the repair of extraction socket defects: A technical modi-
fication and case series report. The International Journal of Oral &
Maxillofacial Implants, 25(6), 1246–1252.
Moraschini, V., & Barboza, E. D. (2016). Quality assessment of systematic
reviews on alveolar socket preservation. International Journal of Oral
and Maxillofacial Surgery. doi:10.1016/j.ijom.2016.03.010
Morjaria, K. R., Wilson, R., & Palmer, R. M. (2014). Bone healing after tooth
extraction with or without an intervention: A systematic review of ran-
domized controlled trials. Clinical Implant Dentistry and Related Research,
16(1), 1–20. doi:10.1111/j.1708-8208.2012.00450.x
Nakamura, T., Shinohara, Y., Momozaki, S., Yoshimoto, T., & Noguchi, K.
(2013). Co‐stimulation with bone morphogenetic protein‐9 and
FK506 induces remarkable osteoblastic differentiation in rat
40 FUJIOKA‐KOBAYASHI ET AL.dedifferentiated fat cells. Biochemical and Biophysical Research Commu-
nications, 440(2), 289–294. doi:10.1016/j.bbrc.2013.09.073
Nakamura, T., Shirakata, Y., Shinohara, Y., Miron, R. J., Furue, K., &
Noguchi, K. (2016). Osteogenic potential of recombinant human bone
morphogenetic protein‐9/absorbable collagen sponge (rhBMP‐9/ACS)
in rat critical size calvarial defects. Clinical Oral Investigations, 1–7.
Ramseier, C. A., Rasperini, G., Batia, S., & Giannobile, W. V. (2012).
Advanced reconstructive technologies for periodontal tissue repair.
Periodontology 2000, 59(1), 185–202. doi:10.1111/j.1600-
0757.2011.00432.x
Rosen, V. (2006). BMP and BMP inhibitors in bone. Annals of the New York
Academy of Sciences, 1068, 19–25. doi:10.1196/annals.1346.005
Schroeder, G. D., Hsu, W. K., Kepler, C. K., Kurd, M. F., Vaccaro, A. R.,
Patel, A. A., & Savage, J. W. (2016). Use of recombinant human bone
morphogenetic protein‐2 in the treatment of degenerative
Spondylolisthesis. Spine (Phila Pa 1976), 41(5), 445–449. doi:10.1097/
brs.0000000000001228
Schwarz, F., Rothamel, D., Herten, M., Ferrari, D., Sager, M., & Becker, J.
(2008). Lateral ridge augmentation using particulated or block bone
substitutes biocoated with rhGDF‐5 and rhBMP‐2: An immunohisto-
chemical study in dogs. Clinical Oral Implants Research, 19(7),
642–652. doi:10.1111/j.1600-0501.2008.01537.x
Shinohara, Y., Nakamura, T., Shirakata, Y., & Noguchi, K. (2016). Bone
healing capabilities of recombinant human bone morphogenetic pro-
tein‐9 (rhBMP‐9) with a chitosan or collagen carrier in rat calvarial
defects. Dental Materials Journal, 35(3), 454–460. doi:10.4012/
dmj.2015-242
Song, J. J., Celeste, A. J., Kong, F. M., Jirtle, R. L., Rosen, V., & Thies, R. S.
(1995). Bone morphogenetic protein‐9 binds to liver cells and stimu-
lates proliferation. Endocrinology, 136(10), 4293–4297. doi:10.1210/
endo.136.10.7664647
Spagnoli, D., & Choi, C. (2013). Extraction socket grafting and buccal wall
regeneration with recombinant human bone morphogenetic protein‐2
and acellular collagen sponge. Atlas of the Oral and Maxillofacial Surgery
Clinics of North America, 21(2), 175–183. doi:10.1016/j.
cxom.2013.05.003
Tan, W. L., Wong, T. L., Wong, M. C., & Lang, N. P. (2012). A systematic
review of post‐extractional alveolar hard and soft tissue dimensional
changes in humans. Clinical Oral Implants Research, 23(Suppl 5), 1–21.
doi:10.1111/j.1600-0501.2011.02375.xTannoury, C. A., & An, H. S. (2014). Complications with the use of bone
morphogenetic protein 2 (BMP‐2) in spine surgery. The Spine Journal,
14(3), 552–559. doi:10.1016/j.spinee.2013.08.060
Wallace, S. (2015). Histomorphometric and 3D cone‐beam computerized
tomographic evaluation of socket preservation in molar extraction sites
using human particulate mineralized Cancellous allograft bone with a
porcine collagen xenograft barrier: A case series. The Journal of Oral
Implantology, 41(3), 291–297. doi:10.1563/aaid-joi-D-14-00078
Wallace, S. C., Pikos, M. A., & Prasad, H. (2014). De novo bone regeneration
in human extraction sites using recombinant human bone morphoge-
netic protein‐2/ACS: A clinical, histomorphometric, densitometric, and
3‐dimensional cone‐beam computerized tomographic scan evaluation.
Implant Dentistry, 23(2), 132–137. doi:10.1097/id.0000000000000035
Wang, J. H., Liu, Y. Z., Yin, L. J., Chen, L., Huang, J., Liu, Y., … He, B. C.
(2013). BMP9 and COX‐2 form an important regulatory loop in
BMP9‐induced osteogenic differentiation of mesenchymal stem cells.
Bone, 57(1), 311–321. doi:10.1016/j.bone.2013.08.015
Yokota, M., Kobayashi, Y., Morita, J., Suzuki, H., Hashimoto, Y., Sasaki, Y., …
Moriyama, K. (2014). Therapeutic effect of nanogel‐based delivery of
soluble FGFR2 with S252 W mutation on craniosynostosis. PloS One,
9(7) e101693. doi:10.1371/journal.pone.0101693
Zhang, Y., Yang, S., Zhou, W., Fu, H., Qian, L., & Miron, R. J. (2015). Addition
of a synthetically fabricated osteoinductive biphasic calcium phosphate
bone graft to BMP2 improves new bone formation. Clinical Implant
Dentistry and Related Research. doi:10.1111/cid.12384
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the
supporting information tab for this article.
How to cite this article: Fujioka‐Kobayashi M, Schaller B,
Saulacic N, Pippenger BE, Zhang Y, Miron RJ. Absorbable colla-
gen sponges loaded with recombinant bone morphogenetic
protein 9 induces greater osteoblast differentiation when com-
pared to bone morphogenetic protein 2. Clin Exp Dent Res.
2017;3:32–40. https://doi.org/10.1002/cre2.00055
